Revance Therapeutics, Inc. (RVNC), Monday announced the pricing of offering of 16 million shares at $6.25 a share, to raise $100 million.
The company said that it plans to use the proceeds to finance the commercial growth of its aesthetics portfolio, including DAXXIFY and the RHA Collection of dermal fillers, support the launch of DAXXIFY into the therapeutics market, and for working capital.
The offering is expected to close on or about March 6.
Barclays acts as the sole book-running manager for the proposed offering.
Currently, Revance's stock is moving down 15.04 percent, to $5.93 over the previous close of $6.98 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.